Veracyte
Yahoo Finance • 5 hours ago
Natera & Angiex Partner to Evaluate AGX101 Response With Signatera
Natera NTRA recently announced a collaboration with Angiex, Inc. to assess treatment response to AGX101, an investigational nuclear-delivered antibody-drug conjugate (ND-ADC), using its Signatera test. The Phase 1 trial is evaluating AGX10... Full story
Yahoo Finance • 9 hours ago
Should You Add Illumina Stock to Your Portfolio Now?
Illumina Inc. ILMN is well positioned for growth in the coming quarters, driven by strategic execution focused on growing its core sequencing business, expanding multiomics and developing services, data and software capabilities. Ongoing m... Full story
Yahoo Finance • yesterday
McKesson to Acquire Precision Medicine Group to Strengthen Services
McKesson Corporation MCK recently announced a definitive agreement to acquire Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization services. The transaction is expected to strengthen McKesso... Full story
Yahoo Finance • yesterday
Is This the Right Time to Hold Medtronic Stock in Your Portfolio?
Medtronic plc MDT is well-poised for growth in the upcoming quarters due to strong momentum in its Cardiovascular businesses, both in the United States and internationally. In Neuroscience, the company is investing across the portfolio to... Full story
Yahoo Finance • 3 days ago
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
McKesson's MCK prospects are being driven by robust growth in specialty distribution, oncology services and biopharma solutions. Earnings are also improving on the back of ongoing operational efficiency and capital discipline despite persi... Full story
Yahoo Finance • 3 days ago
Bausch + Lomb Advances Two First-in-Class Eye Health Therapies
Bausch + Lomb BLCO recently announced that two first-in-class pharmaceutical pipeline candidates will advance to the next stages of clinical development following positive trial results. The programs include a dual-action eye drop for dry... Full story
Yahoo Finance • 3 days ago
Should You Continue to Hold Labcorp Stock in Your Portfolio?
Labcorp Holdings Inc. LH, or Labcorp, is set to benefit from the expansion of its testing capabilities in strategic high-growth areas, including neurology and autoimmune disease. The company's efforts to enhance its partnership with hospit... Full story
Yahoo Finance • 4 days ago
AMN Stock Rallies Nearly 119% YTD: What's Behind the Momentum?
AMN Healthcare Services AMN stock has jumped 118.7% year to date, significantly outperforming its industry's 10.9% gain and the S&P 500's 11.7% growth. The rally reflects improving demand across staffing businesses, stronger execution and... Full story
Yahoo Finance • 4 days ago
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health, Inc. OPK is well-positioned for growth in the coming quarters, supported by the potential of RAYALDEE. Optimism surrounding the stock is driven by RAYALDEE's strong performance, strategic partnerships, BioReference restructuri... Full story
Yahoo Finance • 8 days ago
Is Zimmer Biomet Stock Worth Retaining in Your Portfolio Now?
Zimmer Biomet ZBH appears well positioned for growth in the coming quarters, supported by healthy orthopedic procedure demand. Also, the company is experiencing strong adoption of Z1, HAMMR and OrthoGrid. Yet, intense competition and an el... Full story
Yahoo Finance • 29 days ago
Veracyte (VCYT) Rises with Upward Guidance Revision and Earnings Beat
Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for "Meridian Small Cap Growth Fund". A copy of the letter can be downloaded here. The U.S. market saw a strong rally in the second quarter, fu... Full story
Yahoo Finance • last month
Veracyte to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will be participating in the following investor conferences: Canaccord Genuity 4... Full story
Yahoo Finance • last month
Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?
The First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) provides concentrated, high-conviction exposure to biotechnology firms, while the Vanguard Health Care ETF (NYSEMKT:VHT) offers a cheaper, diversified basket across the entir... Full story
Yahoo Finance • last month
Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?
Key Points iShares Global Healthcare ETF provides broad exposure to 110 global stocks while First Trust NYSE Arca Biotechnology Index Fund concentrates on 30 biotech positions. iShares Global Healthcare ETF carries a lower expense ratio... Full story
Yahoo Finance • last month
Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?
Investors choosing between the State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) and First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) must weigh XLV's broad healthcare diversification and low cost against FBT's conc... Full story
Yahoo Finance • last month
VCYT Crosses Above Average Analyst Target
In recent trading, shares of Veracyte Inc (Symbol: VCYT) have crossed above the average analyst 12-month target price of $32.83, changing hands for $34.02/share. When a stock reaches the target an analyst has set, the analyst logically ha... Full story
Yahoo Finance • 2 months ago
Cathie Wood reshuffles portfolio ahead of Q2, buys SpaceX, Eli Lilly, Meta; pares AMD, Roku
Cathie Wood's ARK Invest's largest purchase during the last week by value was Elon Musk's Space Exploration Technologies (SPCX [https://seekingalpha.com/symbol/SPCX]), adding a combined 349K shares across ARKK, ARKQ, ARKW and ARKX for ~$52... Full story
Yahoo Finance • 2 months ago
Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?
Comparing First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) and iShares Biotechnology ETF (NASDAQ:IBB) reveals a choice between FBT's highly concentrated portfolio and IBB's broader, market-cap-weighted industry exposure. Both... Full story
Yahoo Finance • 2 months ago
Texas Stock Exchange live in Dallas. Y'all Street takes on Wall Street
Move over, New York and Nasdaq — there's a new stock exchange in Texas. On Monday, the Texas Stock Exchange (TXSE) in Dallas went live — but only for members — as it began test trading of designated securities with live trading set to sta... Full story
Yahoo Finance • 2 months ago
A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.
Jonathan Wygant, Vice President and Chief Accounting Officer of Veracyte (NASDAQ:VCYT), reported the exercise of 24,000 options and immediate open-market sale of the same number of shares for a total transaction value of approximately $1.0... Full story